Search
Returning search results with filters:
Remove filter for
Category: Health products
Remove filter for
Issue: New safety information
Remove filter for
Issue: Product safety
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 8 of 8 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
AlertHealth professional risk communication | 2022-08-29
IMVAMUNE Vaccine: Updated Storage Conditions and Shelf Life
AlertHealth professional risk communication | 2022-07-29
Anticipated shortage of euthanasia products for animals
AlertHealth professional risk communication | 2022-03-10
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12